METHOD FOR DETERMINING SEVERITY OF FIBROUS MYOCARDIAL DAMAGE USING MRT FOR SELECTING CANDIDATES FOR CARDIAC RESYNCHRONISING THERAPY Russian patent published in 2019 - IPC A61B5/00 A61B6/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to cardiology, and can be used to determine patients who are shown cardiac resynchronizing therapy. Magnetic resonance imaging (MRI) of the heart is performed with contrast enhancement. Segmented analysis of a series of left ventricular (LV) images is performed. Myocardial thickness is determined with fibrosis in percentage relative to total thickness of myocardium in each of 17 segments. Volume of myocardial involvement in each segment is calculated. If the lesion volume in the segment corresponds to 25 % and less than the LV myocardial thickness, 1 degree of myocardial fibrosis in the segment is conditionally stated. If lesion is 26–50 %, then degree 2 is conditionally stated. If the lesion volume makes 51–70 %, degree 3 is conditionally stated. If the lesion is more than 70 %, degree 4 is conditionally stated. Number of segments with the same degree of myocardial fibrosis is calculated. Fibrosis index (IF) is calculated by the claimed formula. If the IF value is less than 15, the expected effectiveness of the cardiac resynchronizing therapy is high, in this case the viable LV tissue volume is sufficient to provide reverse remodeling. If the IF value is 20 or more, the expected efficacy of the cardiac resynchronizing therapy is low, in which case the fibrous tissue severity is so high that the probability of LV reverse remodeling is extremely low.

EFFECT: method enables simplifying and accelerating the analysis of MPT images without loss of quality and accuracy of determining fibrotic myocardial damage by using a combined semi-quantitative image analysis with determining a myocardial fibrosis index.

1 cl, 2 ex